What Innerwell does

Innerwell (legal entity KBS, Inc.) is a US-based direct-to-consumer telehealth platform that delivers integrated mental health care combining traditional psychiatry, psychotherapy, at-home ketamine-assisted therapy, psychedelic integration, and EMDR. The company operates its own Innerwell App that consolidates psychiatrist scheduling, therapist matching, and patient-reported mood/symptom tracking into a single care coordination interface. Clinicians are licensed across psychiatry, psychiatric nursing, and psychotherapy with specialty training in ketamine administration, EMDR, and modalities including CBT, DBT, and psychodynamic therapy.

The platform monetizes primarily through tiered subscription ketamine programs — Foundation ($998-$1,098 for 8 ketamine experiences plus 4 clinician/therapy sessions) and Extended ($2,000-$2,100 for 24 ketamine experiences plus 6 sessions) — supplemented by per-session EMDR at $165 and traditional psychiatry/therapy services billed through insurance or out-of-network superbills. The company accepts major US insurers including United Healthcare, Anthem, Cigna, Aetna, Magellan Health, Optum, Tricare, and BlueCross BlueShield, and supports HSA/FSA payments with installment plans.

Innerwell serves adult consumers with treatment-resistant depression, anxiety, PTSD, OCD, trauma, and related conditions across 37+ US states. The company was founded in 2022 and closed a $3M pre-seed round led by Greycroft (with Max Ventures and Looking Glass Capital) in June 2022. Headcount is 11-50, and the company reports that 87% of patients report improvement in depression and anxiety within 4 weeks.

Name

Innerwell

Legal name

KBS, Inc.

Website

https://www.helloinnerwell.com/

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

Innerwell is a US direct-to-consumer telehealth platform delivering integrated mental health care, including at-home ketamine-assisted psychotherapy, psychiatry, talk therapy, EMDR, and psychedelic integration, to adults with treatment-resistant depression, anxiety, PTSD, and trauma across 37+ states.

Ownership category

akta.pro rank

Product category

Telehealth Mental Health Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

General Mental Health Therapy Platforms (Talk Therapy) (HLALAEAA)

akta.pro secondary industries

Psychiatry & Medication Management Platforms (HLALAEAB), Outpatient Mental Health & Counseling Clinics (HLAFABAC)

Keywords

• Psychedelic teletherapy
• Ketamine assisted therapy
• Telehealth psychiatry
• At-home mental health
• EMDR therapy services

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Ketamine Therapy Programs: Innerwell generates revenue through ketamine-assisted psychotherapy programs. They offer a Foundation Program with 8 ketamine experiences plus clinical sessions ($998 upfront or $1,098 in installments) and an Extended Program with 24 ketamine experiences ($2,000 upfront or $2,100 in installments).
2. EMDR Therapy: EMDR (Eye Movement Desensitization and Reprocessing) therapy sessions offered at $165 per consultation for new patients.
3. Psychiatric Services: Traditional psychiatry and therapy services providing prescription medicine programs and various psychotherapy modalities including CBT, DBT, and psychodynamic therapy.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Innerwell operates a direct-to-consumer telehealth platform that connects patients with licensed psychiatric clinicians and psychotherapists for at-home mental health care. Its core offerings include ketamine-assisted psychotherapy programs (Foundation and Extended tiers), traditional psychiatry with prescription management, multiple therapy modalities (CBT, DBT, psychodynamic), psychedelic integration sessions, and EMDR therapy. All services are delivered virtually with mail-delivered ketamine medication, supported by a proprietary app for mood/symptom tracking and coordinated care.

Product overview

Innerwell is a telehealth mental health platform offering a unified suite of services including psychiatry, therapy, ketamine therapy, psychedelic integration, and EMDR. The platform connects patients with licensed psychiatric clinicians and psychotherapists through its proprietary app, providing coordinated care under one roof. The core offerings include ketamine-assisted psychotherapy programs (Foundation and Extended) alongside traditional psychiatric and talk therapy services, all delivered via telehealth with insurance acceptance.

Differentiator

Problem solved

Functional benefit

Products and services

• Psychiatry Services Prescription medicine programs continuously optimized based on patient mood and symptoms, delivered by psychiatric clinicians specializing in precision medicine for adults with depression, anxiety, PTSD, OCD, and related conditions.
• Therapy Services Psychotherapy delivered by licensed psychotherapists trained in multiple modalities including CBT, DBT, and psychodynamic therapy, available virtually on demand via Innerwell's telehealth platform.
• Ketamine Therapy At-home ketamine-assisted psychotherapy provided by licensed experts with specialized training in ketamine for treatment-resistant depression and anxiety, with medication shipped to patients for in-home administration.
• Psychedelic Integration Specialized psychotherapy sessions with licensed therapists trained to help patients process and integrate psychedelic experiences and find personal breakthroughs.
• EMDR Therapy Eye Movement Desensitization and Reprocessing therapy delivered by licensed experts to help patients heal past trauma, priced at $165 per consultation with access to self-care resources via the patient portal.

Quantifiable outcome

• 87% of patients report improvements in depression and anxiety within 4 weeks

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• BetterHelp: BetterHelp is the largest online talk therapy platform, operating across all 50 states with a subscription teletherapy model. It serves as a broad incumbent in the general mental health teletherapy category that Innerwell's therapy arm competes with for non-ketamine patients.
• Cerebral: Cerebral is a large mental health telehealth subscription platform offering therapy, psychiatry, and medication management. While facing recent regulatory scrutiny, it remains a broad incumbent in the same subscription-based, DTC virtual mental health space as Innerwell.
• Talkiatry: Talkiatry is a national psychiatric telehealth platform in-network with most major US insurers, providing medication management and therapy. It directly competes with Innerwell's psychiatry and therapy offerings, with substantially more funding and a broader clinician base.
• Hims & Hers: Hims & Hers is a major consumer telehealth platform that has expanded into mental health (anxiety and depression treatment). Its scale, DTC brand, and prescribing infrastructure pose a competitive threat if it extends into ketamine or psychedelic-assisted services.

Emerging players

• Compass Pathways: Compass Pathways is a clinical-stage psychedelic therapy company developing psilocybin treatment for treatment-resistant depression. While currently research-focused rather than commercial, its eventual FDA-approved therapy could either compete with or validate Innerwell's psychedelic teletherapy model.
• Lyra Health: Lyra Health is a mental health benefits platform providing therapy, coaching, and psychiatric care to employees of large enterprises. It competes for the same treatment-resistant, high-acuity patient cohort Innerwell serves, albeit through employer-sponsored distribution rather than DTC.
• Field Trip Health: Field Trip Health operates psychedelic-assisted therapy clinics and is developing at-home ketamine protocols. Its clinical psychedelic expertise and dual clinic/telehealth strategy make it a relevant adjacent competitor in psychedelic mental health treatment.
• Spring Health: Spring Health is a fast-growing mental health platform primarily serving employers with therapy, psychiatry, and care navigation. While B2B-focused, its integrated multi-modality mental health model and expanding service portfolio overlap meaningfully with Innerwell's integrated care thesis.

Direct peers

• Joyous: Joyous provides at-home ketamine teletherapy focused on treatment-resistant depression with a similar subscription-based pricing model. Its direct-to-consumer model and emphasis on low-dose ketamine protocols overlap directly with Innerwell's core ketamine programs.
• Mindbloom: Mindbloom is the closest direct competitor, offering at-home ketamine therapy for depression and anxiety with a telehealth clinician network across multiple US states. Both companies target treatment-resistant patients with mail-delivered, clinician-supervised ketamine protocols, making the product, customer base, and regulatory exposure near-identical.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/HelloInnerwell

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innerwell